Tetra Discovery Partners, a Grand Rapids MI-based pharmaceutical startup developing treatments for memory loss and cognitive impairment, closed $1m funding round.
The round was led by Grand Angels Fund II with participation from Invest Michigan, Biosciences Research & Commercialization Center, Muskegon Angels and J &J Investments.
The company intends to use the funds to accelerate development as it prepares for clinical trials in Fall 2015.
Founded by CEO by Dr. Mark Gurney, Tetra Discovery Partners is developing a platform of drug products to treat cognitive impairment. Tetra drugs target a family of related enzymes known as Type 4 phosphodiesterases (PDE4). The lead drug targeting PDE4D is being developed for treating cognitive impairment in Alzheimer’s disease or schizophrenia with potential applications for Huntington’s disease.